Clinical Trials
3 trialsNCT01236586 2017-07-02
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT01088763 2014-11-05
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00102609 2013-01-10
A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 1 Completed